{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["ivosidenib"],["enasidenib"]],"indication":"IDH1/IDH2-mutated acute myeloid leukemia or myelodysplastic syndrome EB2","name":"HOVON 150 AML","nct_id":"NCT03839771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=hovon-150-aml-nct03839771. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HOVON150AML","arms":[{"description":"Cycle 1: day 1-start cycle 2 \\| Cycle 2: day 1 - start consolidation treatment \\| Consolidation treatment: day 1 - start maintenance \\| Maintenance treatment: day 1- day 730 (2 years) \\|\n\nThe dosage for Placebo for AG-120 (IDH1): 500 mg dose/day\n\nThe dosage for Placebo for AG-221 (IDH2): 100mg dose/day","label":"Arm A: Placebo","type":"PLACEBO_COMPARATOR"},{"description":"Cycle 1: day 1-start cycle 2 \\| Cycle 2: day 1 - start consolidation treatment \\| Consolidation treatment: day 1 - start maintenance \\| Maintenance treatment: day 1- day 730 (2 years) \\|\n\nThe dosage for AG-120 (IDH1): 500 mg dose/day\n\nThe dosage for AG-221 (IDH2): 100mg dose/day","label":"Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)","type":"EXPERIMENTAL"}],"collaborators":["University of Ulm"],"completion_date":{"date":"2034-09-19","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome With Excess Blasts-2"],"enrollment":{"count":968,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AG-120","otherNames":["Ivosidenib"],"type":"DRUG"},{"name":"Placebo for AG-120","otherNames":[],"type":"DRUG"},{"name":"AG-221","otherNames":["Enasidenib"],"type":"DRUG"},{"name":"Placebo for AG-221","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","official_title":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-04-17","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free survival (EFS)","timeFrame":"Approximately up to 60 months following first patient enrollment"}],"references":[],"start_date":{"date":"2019-03-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","url":"https://clinicaltrials.gov/study/NCT03839771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/hovon-150-aml-nct03839771"}